drugset / Trial / NCT03449082

Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)

NCT03449082

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of intra-tendon injection of allogeneic adipose-derived mesenchymal stem cells (Allo-ASC) in intractable common extensor tendinosis patients in comparison with a control treatment.

Timeline

Start
2018-03-15
Primary completion
2019-07-16
Completion
2021-03-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLO-ASC Cell therapy 1 cells Other
Subject ALLO-ASC Cell therapy 10 cells Other
Background Fibrinogen Concentrate Human Protein / enzyme biologic 0.5 ml Other

Indications